Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q2 FY25 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation, Nov 13, 2024
Slide 1: Cover letter to NSE: Investor Presentation
November 13,2024 To, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations a
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
_j_ _______ Disclaimer I I I I I I I Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors th
Slide 4: Contents
Contents 04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap • • • • • • • • • • • • • • • -r '' • • '' '' Balaxi 3
Slide 5: Bridging the Supply Gap in Frontier Markets
_j _ _ Bridging the Supply Gap in Frontier Markets • • • • • • • • • • Branded IPR-based pharma Presence in OTC segments including • • • • company strong branded generics portfolio • • • • • • Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast por
Slide 6: Successful Produce, Stock, Sell Business Model
_j_ _______ Successful Produce, Stock, Sell Business Model I I I I I I I Established operations: Guatemala (Latin America), Dominican Republic (Caribbean) and Expansion initiated: Markets Angola (Africa) Ecuador, Chile (Latin America) New operations: Hondurus, El Salvador, Nicaragua and Central Afri
Slide 7: Key Success Factors
_ j_______ _ • • Key Success Factors • • I I I I I I I • • • • • • • • • • • • Market Selection Methodology • • • • Focus on countries with high-potential economic growth framework • • • • Identify non-English speaking countries with similar characteristics Low competitive intensity and potent
Slide 8: Transition from Asset Light to Asset Right
_ j_______ _ • • • • Transition from “Asset Light” to “Asset Right” I I I I I I • • • • I • • • • • • • • • • • • • • Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution,
Slide 9: Investment in Manufacturing Facilities
_j_ _______ • • • • Investment in Manufacturing Facilities I I I I I • • • • I I • • • • • • • • • • • • • • Setting up its first pharmaceutical formulation manufacturing unit • • General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows
Slide 10: Global Footprint
_ j_______ _ Global Footprint ~-"; ~ ...~ ,~~=s; - • Dominican Portugal China • Existing Market Guatemala El Salvador Republic Honduras Nicaragua Central African India }~,. •. Targeted Expansion Product Sourcing Regions Republic Ecuador Angola if-~ _,, -:--r "" Chile Existing/targeted markets have a
Slide 11: Key Milestones
_ j _______ Key Milestones I I I I I • • • • I I • • • • • • • • • • • • • • • • • • • • • • • • • • Started business supplying • • • • white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP c
Slide 12: Corporate Structure
_j_ _______ Corporate Structure I I I I I I I Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) I I I I r-----------------r------------------,--------------L-~------------------i _______________ i ________________ _ I I I I I I I I I I I I ... I ... I ... I ... I ... I ... I Balaxi Bala
Slide 13: Experienced Board of Directors
_j_ _______ Experienced Board of Directors I I I I I I I Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich
Slide 14: Dynamic Leadership Team
_ j_______ _ • • • • • • Dynamic Leadership Team I I I I I I I • • • • • • Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Comm
Slide 15: Financial Highlights
_J- - - - 1 I I I • • I I I • • • • • • • • • • • • • • • • • • FINANCIAL f. HIGHLIGHTS Balaxi 14
Slide 16: Management's Comments
• • _j_ _______ • • • • • • • • Management’s Comments I I I I I I I • • • • • • • • rr================================================i1 • • “In Q2 FY25, we observed a notable recovery in Angola where business activities gradually normalizing after the unprecedented event of currency devaluation in
Slide 17: Quarterly Financial Performance (Consolidated)
_j_ _______ Quarterly Financial Performance (Consolidated) I I I I I • • I I • • • • • • • • . • • • • Particulars (INR Crore) Q2 FY25 Q2 FY24 YoY • • • • • • Revenue 77.38 54.72 41.4% Gross Profit 33.21 25.60 29.7% Gross Margin % 42.9% 46.8% (390 bps) EBITDA before exceptional item* 10.58 10.76 (1.
Slide 18: Pharma Product Mix – Q2 FY25
_ j________ • • Pharma Product Mix – Q2 FY25 I I I I I I • • • • I • • • • • • • • Geographies Products • • • • • • Shareholders’ Debt Fixed Assets Working Capital 43% Funds ■ Africa* 41% ■ Branded ■ LATM** Generics 57% ■ 59% Dosage Forms Therapeutic Areas 10% ■ Tablets Antibiotics 31% ■ 14% ■ Injec
Slide 19: Financial Performance (Consolidated): FY24
_j_ _______ Financial Performance (Consolidated): FY24 I I I I I I I • • • • • • • • • • • • • • • • • • . Particulars (INR Crore) FY24 FY23 YoY • • Revenue 241.29 336.43 (28.3%) Gross Profit 112.61 134.01 (16.0%) Gross Margin % 46.7% 39.8% +690 bps EBITDA 5.79 59.17 (90%) EBITDA Margin % 2.40% 17.6
Slide 20: Pharma Product Mix – FY24
_ j________ • • Pharma Product Mix – FY24 I I I I I I • • • • I • • • • • • • • Geographies Products • • • • • • Shareholders’ Debt Fixed Assets Working Capital Funds 36% 47% ■ Africa* ■ Branded 53% ■ LATAM** ■ Generics 64% Dosage Forms Therapeutic Areas 14% ■ Tablets Antibiotics 34% ■ Injectables 4
Slide 21: Core Strategy: Enter, Expand & Excel
_j_ _______ • • • • Core Strategy: Enter, Expand & Excel I I I I I • • • • I I • • • • • • • • • • • • Balaxi in 2020: Business Consolidation • • Presence across Angola, Guatemala and Dominican Republic • • Effective and efficient supply chain model consisting of 38 warehouses and a fleet of own
Slide 22: Thank You
Balaxi Pharmaceuticals Limited Plot No. 409, H.No. 8-2-293, 2nd Floor Maps ~ Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact ® Sunny Purohit • • ~ +91-40-2355-5300 • • • • • • • • 8 sunny@balaxi.com • • • • @ www.balaxipharma.in •
Balaxi Pharmaceuticals — Q2 FY25 Earnings Presentation on 6ix